Cagrilintide + semaglutide (CagriSema) research and evidence overview

CagriSema is the rare peptide combination with real combination trials rather than component-level extrapolation. Two published randomised studies matter: a 32-week phase 2 trial in type 2 diabetes and the 68-week phase 3a REDEFINE 1 obesity trial in 3,417 people. Both show the combination beating either component alone on weight. Both also show a gastrointestinal side-effect burden that scales with the result — nearly 80% of participants in REDEFINE 1 reported GI adverse events. This is genuine clinical-stage evidence, not proof of a marketed product.

Semaglutide is a GLP-1 receptor agonist; cagrilintide is a long-acting analogue of amylin, a hormone co-secreted with insulin that slows gastric emptying and signals satiety through a partly separate brainstem pathway. Combining them is a bet that two satiety mechanisms produce more weight loss than either alone — a bet that, unusually for the peptide field, has been tested directly against both monotherapies in the same randomised trials.

A 32-week, double-blind, phase 2 trial across 17 US sites randomised 92 adults with type 2 diabetes and a BMI of 27 or higher, on metformin with or without an SGLT2 inhibitor, to once-weekly subcutaneous CagriSema (n=31), semaglutide (n=31), or cagrilintide (n=30), all escalated to 2.4 mg (Frias et al., The Lancet 2023, PMID 37364590; NCT04982575).

On the primary endpoint, HbA1c, CagriSema fell 2.2 percentage points versus 1.8 for semaglutide and 0.9 for cagrilintide. The combination beat cagrilintide (estimated treatment difference −1.3 points, 95% CI −1.7 to −0.8, p<0.0001) but not semaglutide (−0.4 points, 95% CI −0.8 to 0.0, p=0.075). On the secondary weight endpoint the separation was clear: −15.6% with CagriSema versus −5.1% with semaglutide and −8.1% with cagrilintide, both p<0.0001.

That split is the most instructive result in the programme. On glucose control the combination did not significantly outperform semaglutide alone; on weight it did, by a wide margin. With 31 people per arm, the trial was also small enough that the non-significant HbA1c comparison could reflect power rather than absence of effect.

REDEFINE 1 is the large trial (Garvey et al., New England Journal of Medicine 2025;393(7):635–647, PMID 40544433; NCT05567796). It enrolled adults without diabetes who had a BMI of 30 or higher, or 27 or higher with at least one obesity-related complication, and randomised 3,417 of them in a 21:3:3:7 ratio to cagrilintide-semaglutide 2.4 mg / 2.4 mg (2,108), semaglutide 2.4 mg alone (302), cagrilintide 2.4 mg alone (302), or placebo (705), with lifestyle intervention in every arm, for 68 weeks.

Estimated mean change in body weight was −20.4% with CagriSema versus −3.0% with placebo — a difference of 17.3 percentage points (95% CI −18.1 to −16.6, p<0.001). Participants on the combination were significantly more likely to reach thresholds of 5%, 20%, 25%, and 30% weight loss. Effects were analysed with the treatment-policy estimand, consistent with intention-to-treat, which is the more conservative of the two conventions used in this trial class.

The tolerability figure belongs beside the efficacy figure: gastrointestinal adverse events affected 79.6% of the CagriSema group versus 39.9% on placebo — nausea, vomiting, diarrhoea, constipation, or abdominal pain — described as mainly transient and mild-to-moderate.

Settled: the combination produces substantially more weight loss than placebo, and more than either component alone, over 68 weeks in a large randomised population.

Not settled: cardiovascular and other hard outcomes; what happens after treatment stops; durability past 68 weeks; and how CagriSema compares head-to-head against tirzepatide, which no published randomised trial has tested directly. Every trial cited here was sponsored by Novo Nordisk, with company employees among the authors — normal for phase 3 development, and a fact readers should hold alongside the numbers.

One practical point. These results describe a manufactured fixed-combination product delivered in a dual-chamber pen at defined doses under trial supervision. Vials sold as "cagrilintide + semaglutide" outside an approved supply chain are not that product, and nothing in REDEFINE 1 speaks to their identity, purity, or dosing.